Skip to main content
logo
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
266.16
+0.89 (0.34%)
Jun 12, 2026, 4:00 PM EDT - Market closed

Labcorp Holdings Revenue by Segment

Period EndingMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
11.01B10.88B10.74B10.52B10.30B10.15B9.91B9.70B
Diagnostics Growth
6.92%7.19%8.43%8.53%8.26%7.82%5.91%5.22%
Drug Development
3.16B3.10B3.07B3.01B2.93B2.92B2.85B2.83B
Drug Development Growth
7.65%6.01%7.78%6.32%3.87%-16.80%-32.26%-42.15%

Operating Income by Segment

Period EndingMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.81B1.78B1.72B1.66B1.62B1.61B1.60B1.60B
Diagnostics Growth
12.08%10.81%7.48%3.61%3.08%0.95%-1.48%-4.68%
Drug Development
512.30M498.50M493.20M481.90M466.00M459.00M437.20M425.30M
Drug Development Growth
9.94%8.61%12.81%13.31%10.30%2.80%-19.93%-34.34%
General Corporate Expenses
-282.90M-276.80M-276.30M-274.20M-268.70M-268.30M-269.00M-273.20M

Operating Expense Breakdown

Period EndingMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.22B2.22B2.27B2.29B2.27B2.23B2.17B2.12B
Selling, General, and Administrative Growth
-2.04%-0.61%4.85%7.74%9.41%5.30%2.18%0.89%
Amortization
286.00M280.00M277.80M272.00M265.90M256.40M245.20M237.20M
Amortization Growth
7.56%9.20%13.30%14.67%17.40%8.78%3.42%-3.81%
Restructuring and Other
127.20M127.20M27.80M39.90M47.40M46.00M52.90M42.40M
Restructuring and Other Growth
168.35%176.52%-47.45%-5.90%1.72%-8.37%21.33%-17.19%
Impairments
4.30M4.30M3.50M2.80M2.80M5.30M336.30M346.50M
Impairments Growth
53.57%-18.87%-98.96%-99.19%-99.20%-98.48%17.79%25.86%